{"id":31775,"date":"2025-09-05T06:28:20","date_gmt":"2025-09-05T06:28:20","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/medidata-secures-a-leader-position-in-everest-groups-peak-matrix-assessment-for-ecoa-driving-the-new-patient-experience-forward\/"},"modified":"2025-09-05T06:28:20","modified_gmt":"2025-09-05T06:28:20","slug":"medidata-secures-a-leader-position-in-everest-groups-peak-matrix-assessment-for-ecoa-driving-the-new-patient-experience-forward","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=31775","title":{"rendered":"Medidata Secures a Leader Position in Everest Group’s PEAK Matrix\u00ae Assessment for eCOA, Driving the New Patient Experience Forward"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and reducing study build timeline by up to 50% compared to the industry standard<\/i><\/p>\n

SINGAPORE<\/span><\/span>, Sept. 5, 2025<\/span><\/span> \/PRNewswire\/ — Medidata<\/a>, a Dassault Syst\u00e8mes brand and leading provider of clinical trial solutions to the life sciences industry, has been recognized as a Leader in Everest Group’s Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix\u00ae Assessment 2025. The report assessed 19 providers based on their demonstrated success in delivering products and driving impact within the life science industry, solidifying Medidata eCOA<\/a> as a powerful solution for clinical trials and medical breakthroughs.<\/p>\n

\n<\/div>\n

“As the Leader in the eCOA market for over a decade, Medidata solutions, services, and support have been foundational to thousands of global studies across every indication,” said Nisarg Shah<\/span>, research director, Everest. “Built on its reputation as the global Leader in clinical research technology, Medidata eCOA continues to revolutionize the market with innovations like Medidata Designer<\/a>, which drastically reduces study design and startup timelines. Medidata’s commitment extends to delivering world-class expert advisory and scientific support services, helping with trial success, higher quality data, and superior experiences for patients and sites alike.”<\/p>\n

Driving the Medidata Patient Experience<\/a> forward, Medidata eCOA combines cutting-edge technology and operational expertise to launch studies faster than the industry standard and maintain top data integrity, reducing study build time by up to six weeks compared to the industry standard of 12 or more weeks. With its recent partnership with Cogstate<\/a>, Medidata eCOA was further enhanced with scientific rigor that aims to reduce rater burden and enhance signal detection in Central Nervous System (CNS) trials.<\/p>\n

“Achieving a Leader position in Everest Group’s eCOA PEAK Matrix\u00ae Assessment underscores Medidata’s relentless pursuit of innovation and our profound impact on enhancing the clinical trial experience for both sites and patients,” said Matt Noble<\/span>, senior vice president, Patient Experience, Medidata.<\/p>\n

Medidata’s consistent recognition by Everest Group in 2023<\/a>\u00a0and 2024<\/a>\u00a0for Decentralized Clinical Trials<\/a> – a core element of the Patient Experience – underscores its leadership in the clinical trial space. Further accolades for Medidata Rave EDC<\/a> and Medidata Rave CTMS<\/a>, integral parts of\u00a0the Medidata Data Experience<\/a>\u00a0and Medidata Study Experience<\/a>, highlight the company’s unwavering dedication to patients, sites, and sponsors, driving improved clinical trial operations and accelerating the delivery of life-saving therapies to market.<\/p>\n

To learn more about Medidata eCOA and the Everest Group report, visit here<\/a> and here<\/a>.<\/p>\n

About Medidata<\/b><\/p>\n

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Syst\u00e8mes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City<\/span> and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com<\/a>. Listen to our latest podcast, from Dreamers to Disruptors<\/i><\/b><\/a>, and follow us at @Medidata.<\/p>\n

About Dassault Syst\u00e8mes<\/b><\/p>\n

Dassault Syst\u00e8mes is a catalyst for human progress. \u00a0Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. \u00a0With Dassault Syst\u00e8mes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. \u00a0For more information, visit: www.3ds.com<\/a>.<\/p>\n

About Everest Group<\/b>\u202f\u00a0
Everest Group is a leading global research firm helping business leaders make confident decisions. Everest Group’s\u202fPEAK Matrix\u00ae\u202fassessments\u202fprovide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the\u202fPEAK Matrix\u00ae\u202fto gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth\u202fcontent at\u202fwww.everestgrp.com<\/a>.\u202f\u00a0<\/p>\n

Disclaimer<\/b>\u202f\u00a0<\/p>\n

Licensed extracts taken from Everest Group’s PEAK Matrix\u00ae Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s\u202fPEAK Matrix\u00ae\u202freports do not necessarily provide the full context of our research and analysis.\u202f All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s\u202fPEAK Matrix\u00ae\u202freports is independent and no organization has paid a fee to be featured or to influence their ranking.\u202f To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix\u00ae Reports<\/a>.\u202f\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and reducing study build timeline by up to 50% compared to the industry standard<\/i><\/p>\n

SINGAPORE<\/span><\/span>, Sept. 5, 2025<\/span><\/span> \/PRNewswire\/ — Medidata<\/a>, a Dassault Syst\u00e8mes brand and leading provider of clinical trial solutions to the life sciences industry, has been recognized as a Leader in Everest Group’s Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix\u00ae Assessment 2025. The report assessed 19 providers based on their demonstrated success in delivering products and driving impact within the life science industry, solidifying Medidata eCOA<\/a> as a powerful solution for clinical trials and medical breakthroughs.<\/p>\n

\n<\/div>\n

“As the Leader in the eCOA market for over a decade, Medidata solutions, services, and support have been foundational to thousands of global studies across every indication,” said Nisarg Shah<\/span>, research director, Everest. “Built on its reputation as the global Leader in clinical research technology, Medidata eCOA continues to revolutionize the market with innovations like Medidata Designer<\/a>, which drastically reduces study design and startup timelines. Medidata’s commitment extends to delivering world-class expert advisory and scientific support services, helping with trial success, higher quality data, and superior experiences for patients and sites alike.”<\/p>\n

Driving the Medidata Patient Experience<\/a> forward, Medidata eCOA combines cutting-edge technology and operational expertise to launch studies faster than the industry standard and maintain top data integrity, reducing study build time by up to six weeks compared to the industry standard of 12 or more weeks. With its recent partnership with Cogstate<\/a>, Medidata eCOA was further enhanced with scientific rigor that aims to reduce rater burden and enhance signal detection in Central Nervous System (CNS) trials.<\/p>\n

“Achieving a Leader position in Everest Group’s eCOA PEAK Matrix\u00ae Assessment underscores Medidata’s relentless pursuit of innovation and our profound impact on enhancing the clinical trial experience for both sites and patients,” said Matt Noble<\/span>, senior vice president, Patient Experience, Medidata.<\/p>\n

Medidata’s consistent recognition by Everest Group in 2023<\/a>\u00a0and 2024<\/a>\u00a0for Decentralized Clinical Trials<\/a> – a core element of the Patient Experience – underscores its leadership in the clinical trial space. Further accolades for Medidata Rave EDC<\/a> and Medidata Rave CTMS<\/a>, integral parts of\u00a0the Medidata Data Experience<\/a>\u00a0and Medidata Study Experience<\/a>, highlight the company’s unwavering dedication to patients, sites, and sponsors, driving improved clinical trial operations and accelerating the delivery of life-saving therapies to market.<\/p>\n

To learn more about Medidata eCOA and the Everest Group report, visit here<\/a> and here<\/a>.<\/p>\n

About Medidata<\/b><\/p>\n

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Syst\u00e8mes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City<\/span> and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com<\/a>. Listen to our latest podcast, from Dreamers to Disruptors<\/i><\/b><\/a>, and follow us at @Medidata.<\/p>\n

About Dassault Syst\u00e8mes<\/b><\/p>\n

Dassault Syst\u00e8mes is a catalyst for human progress. \u00a0Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. \u00a0With Dassault Syst\u00e8mes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. \u00a0For more information, visit: www.3ds.com<\/a>.<\/p>\n

About Everest Group<\/b>\u202f\u00a0
Everest Group is a leading global research firm helping business leaders make confident decisions. Everest Group’s\u202fPEAK Matrix\u00ae\u202fassessments\u202fprovide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the\u202fPEAK Matrix\u00ae\u202fto gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth\u202fcontent at\u202fwww.everestgrp.com<\/a>.\u202f\u00a0<\/p>\n

Disclaimer<\/b>\u202f\u00a0<\/p>\n

Licensed extracts taken from Everest Group’s PEAK Matrix\u00ae Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s\u202fPEAK Matrix\u00ae\u202freports do not necessarily provide the full context of our research and analysis.\u202f All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s\u202fPEAK Matrix\u00ae\u202freports is independent and no organization has paid a fee to be featured or to influence their ranking.\u202f To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix\u00ae Reports<\/a>.\u202f\u00a0<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-31775","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/31775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31775"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/31775\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}